7/19/22, 10:42 AM
`
`ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
`
`https://sciencex.com/wire-news/107531358/ash-honors-bruce-r-blazar-md-and-carl-h-june-md-with-2012-ernest.html
`
`1/4
`
`UPenn Ex. 2040
`Miltenyi v. UPenn
`IPR2022-00855
`
`All News
`Phys.org
`Medical Xpress
`Tech Xplore
`Recaps
`Dialog
`ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest
`Beutler Lecture and Prize
`August 27th, 2012
`The Ernest Beutler Lecture and Prize, named for the late Ernest Beutler, MD, a past president
`of ASH and physician-scientist for more than 50 years, is a two-part lectureship that recognizes
`major translational advances related to a single topic. This award honors two individuals, one
`who has enabled advances in basic science and another for achievements in clinical science or
`translational research.
`Drs. Blazar and June will present their lecture, "T-Cell Infusions: A New Tool for Transfusion
`Medicine That Has Come of Age," on Monday, December 10, at 1:30 p.m. at the 54th ASH
`Annual Meeting and Exposition in Atlanta. During the session, they will discuss the use of
`adoptive T-cell therapy as an emerging form of transfusion therapy that has potential to
`establish tolerance to hematopoietic or solid organs allografts, treat autoimmunity, and
`promote immunity to cancer and chronic infection.
`Dr. Blazar is the Regent's Professor of Pediatrics, Chief of the Pediatric BMT Program, and
`Andersen Chair in Transplantation Immunology at the University of Minnesota (UMN) and is
`internationally recognized as one of the foremost physician-scientists in the eld of BMT. He
`also serves as Associate Vice President of the Academic Health Center and Founding Director
`of both the Clinical and Translational Science Institute and the Center for Translational
`Medicine at the UMN.
`Dr. Blazar has made seminal contributions in dissecting the mechanisms underlying graft-
`versus-host-disease (GVHD), a major complication of BMT, that have been instrumental in
`advancing the eld. His studies have resulted in pivotal trials, bringing novel pharmaceutical
`agents, proteins, and cell therapies to the clinic.
`Specically, Dr. Blazar was the rst to examine the eects of rapamycin, an
`immunosuppressant drug used to prevent rejection after organ transplantation, and
`demonstrated that the drug could inhibit and treat GVHD in preclinical BMT animal models.
`Thanks to this unprecedented work, several international Phase III clinical trials are now
`underway using rapamycin to both prevent and treat GVHD. In addition to this
`

`

`7/19/22, 10:42 AM
`
`ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
`
`https://sciencex.com/wire-news/107531358/ash-honors-bruce-r-blazar-md-and-carl-h-june-md-with-2012-ernest.html
`
`2/4
`
`UPenn Ex. 2040
`Miltenyi v. UPenn
`IPR2022-00855
`
`groundbreaking work, Dr. Blazar's preclinical GVHD studies led to the clinical testing of non-
`mitogenic anti-CD3 monoclonal antibody to target GVHD-causing T cells, demonstration that
`interleukin-10 (IL-10) protein could inhibit GVHD lethality, and keratinocyte growth factor to
`prevent tissue injury in rodents and humans after allogeneic hematopoietic cell
`transplantation. More recently, Dr. Blazar has published the rst report of a novel population
`of regulatory T-cells, known as Tregs, that can be expanded ex vivo and used to prevent and
`eliminate GVHD.
`Dr. Blazar has served in a variety of leadership roles within the Society, most recently as co-
`chair of the 2012 ASH Annual Meeting Scientic Program, and has also served on the editorial
`board of the Society's journal Blood and as chair of the Scientic Committee on
`Transplantation Biology. Aside from his involvement within ASH, Dr. Blazar has worked closely
`with the National Institutes of Health (NIH), having served as chair of the NIH Cancer
`Immunopathology and Immunotherapy Study Section,co-chair of the National Heart, Lung,
`and Blood Institute's Panel for Strategic Planning for Cellular Therapies, Board of Scientic
`Counselors for the National Cancer Institute, and a member of the Food and Drug
`Administration Biological Response Modiers Advisory Committee. He is also an elected
`member of the American Society of Clinical Investigation and the Association of American
`Physicians.
`Over the course of his career Dr. Blazar has received many honors and awards, including an
`NIH Merit Award, the American Society of Blood and Marrow Transplantation's E. Donnall
`Thomas Lecture, and as a Fellow of the American Association for the Advancement of Science.
`He serves as Principal Investigator of numerous NIH R01 grants, including the prestigious NIH
`Clinical and Translational Science Award, and has 14 visiting professorships and lectureships
`from various prestigious institutions and organizations in the United States and United
`Kingdom.
`Dr. June, the Richard W. Vague Professor in Immunotherapy in the department of Pathology
`and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania
`and the director of Translational Research in Penn's Abramson Cancer Center, has not only
`contributed to advances in the understanding of immune cell biology, but has also opened
`new avenues for the immunologic treatment of cancer. Although trained as a clinician, he has
`spent a majority of his career in the laboratory, focusing his research on using immunotherapy
`(using the body's own immune system to help ght disease) as a cure for cancer. He has
`conducted several successful clinical trials of adoptive immunotherapy in which an individual's
`white blood cells are coupled with a naturally produced growth factor to enhance their cancer-
`ghting capacity that have successfully demonstrated adoptive immunotherapy's therapeutic
`potential for cancer.
`O
`f D J
`'
`hi
`i 2011 h
`h
`d hi
`ll
`f ll
`

`

`7/19/22, 10:42 AM
`
`ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
`
`https://sciencex.com/wire-news/107531358/ash-honors-bruce-r-blazar-md-and-carl-h-june-md-with-2012-ernest.html
`
`3/4
`
`UPenn Ex. 2040
`Miltenyi v. UPenn
`IPR2022-00855
`
`One of Dr. June's greatest achievements came in 2011 when he and his colleagues successfully
`used gene therapy to create "serial killer" T cells that successfully attacked leukemic tumor
`cells in three patients with chronic lymphocytic leukemia (CLL). The researchers named these
`genetically enhanced T cells "serial killers," because for every modied T cell infused into the
`patients' blood, at least 1,000 tumor cells were killed. In the trial, 20 years in the making, two
`patients with CLL achieved full remission and one achieved partial remission after receiving
`the genetically engineered immune cells. Results from this landmark study are considered to
`be some of the greatest breakthroughs in leukemia research in recent years.
`In his lab, Dr. June is continuing his adoptive immunotherapy research in blood cancers and is
`working with other scientists and clinicians at University of Pennsylvania to develop protocols
`for expanding his work in solid tumor cancers, including breast, pancreatic, and lung. Recent
`studies, done in collaboration with Stephan Grupp at the University of Pennsylvania, indicate
`that this approach also has promise for refractory pediatric pre-B-cell acute leukemia.
`As a long-time member of the Society, Dr. June has served as chair of the Scientic Committee
`on Lymphocyte Biology, among other volunteer roles. Beyond his involvement with ASH, Dr.
`June has served in various leadership capacities for several other hematology/oncology
`organizations, most notably as past president of the Clinical Immunology Society and chair of
`the Clinical and Regulatory Aairs and Genetic Vaccines Committees at the American Society of
`Gene and Cell Therapy. Dr. June is also the recipient of many prestigious honors within the
`medical eld, including the Leukemia & Lymphoma Society Lifetime Achievement Award, the
`Department of the Navy's Oce of Naval Research's Robert Dexter Conrad Award for Scientic
`Achievement (the Navy's highest award for scientic achievement), the U.S. Medicine Frank
`Brown Berry Prize, and the Bristol-Myers Squibb Freedom to Discover Award.
`"Drs. Blazar and June are great examples of the power of translational research, as their work
`has clearly demonstrated how research conducted at the laboratory bench can translate into
`treatment strategies that signicantly improve clinical practice," said ASH President Armand
`Keating, MD, of Princess Margaret Hospital in Toronto. "Because of the work of these pioneers
`in modern hematology, today's patients are undergoing safer bone marrow transplants and
`hematologists are now using patients' own immune cells to ght cancer – a treatment option
`that was seen only in the lab a few years ago and now is on the way to curing patients."
`Provided by American Society of Hematology
`Citation: ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler
`Lecture and Prize (2012, August 27) retrieved 19 July 2022 from https://sciencex.com/wire-
`news/107531358/ash-honors-bruce-r-blazar-md-and-carl-h-june-md-with-2012-ernest.html
`

`

`7/19/22, 10:42 AM
`
`ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
`
`https://sciencex.com/wire-news/107531358/ash-honors-bruce-r-blazar-md-and-carl-h-june-md-with-2012-ernest.html
`
`4/4
`
`UPenn Ex. 2040
`Miltenyi v. UPenn
`IPR2022-00855
`
`This document is subject to copyright. Apart from any fair dealing for the purpose of
`private study or research, no part may be reproduced without the written permission. The
`content is provided for information purposes only.
`